# OnCo record idea-stack-ctdna-and-tumour-rna-residual-disease (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-stack-ctdna-and-tumour-rna-residual-disease/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-stack-ctdna-and-tumour-rna-residual-disease" ;
  schema:name "Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer"@en ;
  schema:alternateName "Stacking ctDNA and ctRNA"@en, "Multi-analyte residual disease test"@en, "cfDNA plus cfRNA residual disease"@en ;
  schema:description "A proposal, unproven at residual disease levels: add the tumour's RNA to the tumour DNA a blood test already tracks, because a cell holds many more RNA copies of an active gene than DNA copies, and RNA could also show whether the cancer still makes the oestrogen receptor or TROP2."@en ;
  schema:url <https://onco.cc/ideas/idea-stack-ctdna-and-tumour-rna-residual-disease/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1093/annonc/mdx765>, <https://doi.org/10.1038/s41467-021-22444-1>, <https://doi.org/10.1093/clinchem/48.10.1647> ;
  onco:tag "proposal" ;
  onco:related <https://onco.cc/ideas/idea-same-fragment-methylation-and-mutation/>, <https://onco.cc/ideas/idea-bio1-cfrna-plasticity-tracking/> ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-rna-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/estrogen-receptor/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/terms/mrd/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-krug-exosomal-rna-ctdna-egfr-ann-oncol-2018/>, <https://onco.cc/key-papers/paper-larson-cell-free-transcriptome-cancer-nat-commun-2021/>, <https://onco.cc/key-papers/paper-marinov-single-cell-transcriptome-stochasticity-genome-res-2014/>, <https://onco.cc/key-papers/paper-tsui-plasma-rna-stability-clin-chem-2002/>, <https://onco.cc/key-papers/paper-wang-orphan-rnas-breast-response-cell-rep-med-2026/>, <https://onco.cc/key-papers/paper-heeke-alk-ctrna-ctdna-jto-clin-res-rep-2025/>, <https://onco.cc/key-papers/paper-nimir-ar-v7-ctc-ctrna-exosomes-cells-2019/>, <https://onco.cc/key-papers/paper-rampazzo-plasma-tert-rna-rectal-cancer-br-j-cancer-2018/>, <https://onco.cc/key-papers/paper-yen-ev-protein-mrna-ovarian-ebiomedicine-2025/>, <https://onco.cc/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/>, <https://onco.cc/key-papers/paper-northcott-next-personal-validation-oncotarget-2024/>, <https://onco.cc/key-papers/paper-abbosh-tracerx-ctdna-relapse-nature-2023/> .